BR0113752A - Derivados piperidina para uso inibidores 2,3-óxido esqualeno lanoesterol ciclase - Google Patents

Derivados piperidina para uso inibidores 2,3-óxido esqualeno lanoesterol ciclase

Info

Publication number
BR0113752A
BR0113752A BR0113752-2A BR0113752A BR0113752A BR 0113752 A BR0113752 A BR 0113752A BR 0113752 A BR0113752 A BR 0113752A BR 0113752 A BR0113752 A BR 0113752A
Authority
BR
Brazil
Prior art keywords
lanoesterol
piperidine derivatives
squalene
cyclase inhibitors
cyclase
Prior art date
Application number
BR0113752-2A
Other languages
English (en)
Inventor
Jean Ackermann
Johannes Aebi
Alexander Chucholowski
Henrietta Dehmlow
Olivier Morand
Sabine Wallabaum
Thomas Weller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0113752A publication Critical patent/BR0113752A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Abstract

"DERIVADOS PIPERIDINA PARA USO INIBIDORES 2,3-óXIDO ESQUALENO LANOESTEROL CICLASE". A presente invenção refere-se a composto de fórmula (I), onde U,V,W,A^ 1^,A^ 2^,A^ 3^,A^ 4^,A^ 5^,m e n são como definidos na descrição e reivindicações e seus sais farmaceuticamente aceitáveis e/ou seus ésteres farmaceuticamente aceitáveis. Os compostos são úteis para o tratamento e/ou profilaxia de doenças que são associadas com 2,3-óxido esqualeno-lanoesterol ciclase tais como hipercolesterolemia, hiperlipemia, arteriosclerose, doenças vasculares, micoses, cálculos renais, tumores e/ou distúrbios hiperproliferativos, e tratamento e/ou profilaxia de tolerância a glicose prejudicada e diabetes.
BR0113752-2A 2000-09-08 2001-08-29 Derivados piperidina para uso inibidores 2,3-óxido esqualeno lanoesterol ciclase BR0113752A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00119677 2000-09-08
PCT/EP2001/009941 WO2002020483A1 (en) 2000-09-08 2001-08-29 Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors

Publications (1)

Publication Number Publication Date
BR0113752A true BR0113752A (pt) 2003-07-29

Family

ID=8169794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113752-2A BR0113752A (pt) 2000-09-08 2001-08-29 Derivados piperidina para uso inibidores 2,3-óxido esqualeno lanoesterol ciclase

Country Status (15)

Country Link
US (1) US6964974B2 (pt)
EP (1) EP1317432B1 (pt)
JP (1) JP2004508354A (pt)
KR (1) KR20030027122A (pt)
CN (1) CN1231466C (pt)
AR (1) AR032634A1 (pt)
AT (1) ATE384047T1 (pt)
AU (1) AU2001285912A1 (pt)
BR (1) BR0113752A (pt)
CA (1) CA2419588C (pt)
DE (1) DE60132468T2 (pt)
ES (1) ES2298253T3 (pt)
MX (1) MXPA03002034A (pt)
WO (1) WO2002020483A1 (pt)
ZA (1) ZA200301818B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4244139B2 (ja) 2000-08-16 2009-03-25 エフ．ホフマン−ラ ロシュ アーゲー 新規アミノシクロヘキサン誘導体
JP2005518376A (ja) 2001-12-14 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 化合物およびホルモン感受性リパーゼの活性を低下させるためのその使用
US7012077B2 (en) * 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
BRPI0519288A2 (pt) * 2004-12-24 2009-01-06 Astrazeneca Ab compostos heterocÍclicos como antagonistas de ccr2b
WO2012092114A2 (en) * 2010-12-27 2012-07-05 The Curators Of The University Of Missouri Oxidosqualene cyclase as a protein target for anticancer therapeutics
EP2768512A4 (en) * 2011-10-20 2015-05-13 Univ Missouri ENZYME HAMMER FOR CANCER TREATMENT

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
US3914426A (en) * 1972-11-10 1975-10-21 Pfizer Piperidinesulfonylurea derivatives for lowering blood sugar levels
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
JPH08504194A (ja) 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
FR2705343B1 (fr) 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
GB9310066D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
TW438774B (en) 1993-07-14 2001-06-07 Hoffmann La Roche Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines
MA23420A1 (fr) 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
DE4407961A1 (de) 1994-03-10 1995-09-14 Thomae Gmbh Dr K Imidazolidin-2-one, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2190699A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19618970A1 (de) 1996-05-10 1997-11-13 Klinge Co Chem Pharm Fab Neue Thiazolopyridine
US6025372A (en) * 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
CA2285335A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. Selective factor xa inhibitors
DE19806713A1 (de) 1998-02-18 1999-08-19 Boehringer Ingelheim Pharma Neue Urethane, ihre Thio- und Dithioanaloga, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CA2419588C (en) 2009-09-22
ZA200301818B (en) 2004-06-21
CA2419588A1 (en) 2002-03-14
EP1317432A1 (en) 2003-06-11
KR20030027122A (ko) 2003-04-03
JP2004508354A (ja) 2004-03-18
CN1231466C (zh) 2005-12-14
MXPA03002034A (es) 2003-07-24
AR032634A1 (es) 2003-11-19
DE60132468T2 (de) 2009-01-15
DE60132468D1 (de) 2008-03-06
WO2002020483A1 (en) 2002-03-14
CN1468220A (zh) 2004-01-14
AU2001285912A1 (en) 2002-03-22
ATE384047T1 (de) 2008-02-15
US6964974B2 (en) 2005-11-15
ES2298253T3 (es) 2008-05-16
EP1317432B1 (en) 2008-01-16
US20020068753A1 (en) 2002-06-06
WO2002020483A8 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
BRPI0417458A (pt) compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
BG66094B1 (bg) Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства
BRPI0108394B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
MX9707453A (es) Derivados de quinazolina.
BR9713552A (pt) Derivados de pirimidina bicìclicos condensados
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR0307267A (pt) Compostos heterocìclicos, ativos como inibidores de beta-lacta-mases
BR0215396A (pt) Compostos, processo para a manufatura de compostos, composições farmacêuticas, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com "dpp-iv" e utilização dos compostos
BR9712672A (pt) Derivados heterocìclicos que inibem o fator xa
BR0112395A (pt) Derivados de benzotiazol
BR0212929A (pt) Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de compostos, e método para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, disfunção renal, distúrbios alimentares e obesidade
BR0309012A (pt) Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0015254C1 (pt) compostos derivados de carbamoiloxialquil-azólio, seu uso, bem como composição farmacêutica compreendendo os mesmos.
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0108605A (pt) Derivados de 8,8a-dihidro-indeno[1,2-d]tiazol, que na posição 8a são substituìdos; processos para a sua preparação e seu emprego como medicamentos, por exemplo, como anoréxicos
BRPI0414630A (pt) derivados ciclohexìlicos substituìdos com aminoalquilamida
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
BR0115045A (pt) Compostos, processo para sua preparação, composição farmacêutica que compreende os mesmos, sua utilização, processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
BR0308108A (pt) Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.